The HMHB Consortium works with partners to advocate for collective action and intentional, innovative, and systematic investment in scaling maternal nutrition interventions, specifically multiple micronutrient supplementation (MMS). National governments and their development partners need the correct information, evidence, tools, and MMS-relevant policies necessary to adopt and scale MMS as well as the financing to support maternal health programs that include MMS at the country level. Therefore, HMHB has developed a range of resources to guide and assist national partners, advocates, public health professionals, national health officials, and partners in NGOs, research, academia, program implementors, as well as local providers and distributors.
The Advocacy Toolkit for MMS consists of an adaptable slide deck, an advocacy brief, a frequently asked questions brief, and an HMHB Consortium factsheet. The toolkit summarizes evidence on pregnancy and nutrition, the scale and scope of maternal malnutrition, research on MMS, a national investment case, steps for introducing and scaling MMS, and finally, a case study performed in Indonesia. It is available in French, Spanish, and Arabic. Other resources include five, unique, short films, called ‘Women’s Voices‘ that lift up women’s voices in different global contexts, an advocacy brief and frequently asked questions on the inclusion of MMS in WHO’s EML, various articles, blogs, and op-eds, and recordings of webinars lifting up women’s nutrition, health, and equity issues during global moments.
This Advocacy Brief is meant to equip champions and decision-makers to advocate for safe, affordable, and cost-effective nutrition interventions, particularly multiple micronutrient supplementation (MMS) to improve maternal health.
This Advocacy Brief describes the case for nutrition resilience of mothers and their babies, particularly the in implementation and scale up access to proven solutions, like antenatal MMS.
This Advocacy Brief and FAQ document answers questions related to the inclusion of MMS in WHO’s Essential Medicines List to support national advocacy efforts.